The Committee For Medicinal Products For Human Use (CHMP) Reaffirms Positive Opinion For ...
Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...
来自MSN1 小时
KRYS Gets Positive CHMP Opinion for EU Approval of Skin Disease Drug
Krystal Biotech KRYS announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has ...
Novartis Gets CHMP Opinion for Label Expansion of Fabhalta
The CHMP recommends granting a marketing authorization to NVS' Fabhalta for the treatment of adults with C3 glomerulopathy, an ultra-rare, progressive kidney disease with no currently approved ...
Morningstar3 天
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for ...
Viehbacher, "Biogen") announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has reaffirmed its positive opinion by consensus for the anti ...
渤健与卫材称欧洲监管机构重申对阿尔茨海默病药物的支持
渤健和卫材周五表示，欧洲药品管理局人用药品委员会（Committee for Medicinal Products for Human Use）已重申其建议批准其阿尔茨海默病药物Leqembi（仑卡奈单抗）。 这两家公司周五表示，欧盟委员会曾要求该小组考虑在11月通过积极意见后获得的有关Leqembi安全性的信息，欧盟委员会将恢复其药物上市许可的决策过程。
PMLiVE6 小时
Rare diseases: CHMP recommends Krystal’s Vyjuvek for dystrophic epidermolysis bullosa
The European Medicines Agency’s (EMA) human medicines committee has recommended Krystal Biotech’s Vyjuvek (beremagene ...
Morningstar3 天
The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for ...
28, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European ...
The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has reaffirmed its ...
BioArctic: The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that the Committee for Medicinal Products for Human Use (CHMP) ...
Daily13 小时
Novartis oral Fabhalta receives positive EMA Committee opinion for adults with C3 ...
Basel: Novartis has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...
Pharmabiz14 小时
EMA committee recommends marketing approval for Novartis oral Fabhalta to treat adults ...
EMA committee recommends marketing approval for Novartis oral Fabhalta to treat adults living with C3 glomerulopathy: Basel Monday, March 3, 2025, 10:00 Hrs [IST] Novartis announc ...
BioWorld3 天
Leqembi gets another thumbs-up amid CHMP February recommendations
The EMA’s Committee for Medicinal products for Human Use (CHMP) is standing by its opinion on Leqembi (lecanemab) after the European .mission pushed back against a recommendation in November 2024 that ...